Boston Scientific Corporation (0HOY.L)
USD 99.4
(4.75%)
USD 99.4
(4.75%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.61 Billion USD | 22.06% |
| 2022 | 3.16 Billion USD | -1.82% |
| 2021 | 2.91 Billion USD | 74.99% |
| 2020 | 1.51 Billion USD | -36.7% |
| 2019 | 2.21 Billion USD | 3.46% |
| 2018 | 2.61 Billion USD | 11.06% |
| 2017 | 2.44 Billion USD | 15.5% |
| 2016 | 2.2 Billion USD | 10.92% |
| 2015 | 360 Million USD | 10.13% |
| 2014 | 433 Million USD | 5.4% |
| 2013 | 721 Million USD | -2.63% |
| 2012 | -3.16 Billion USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 948 Million USD | 7.2% |
| 2024 Q2 | 1.11 Billion USD | 11.33% |
| 2024 Q3 | 747 Million USD | -4.68% |
| 2023 Q3 | 859 Million USD | 1.18% |
| 2023 Q4 | 871 Million USD | 1.4% |
| 2023 Q1 | 800 Million USD | 7.67% |
| 2023 Q2 | 849 Million USD | 6.13% |
| 2023 FY | - USD | 14.09% |
| 2022 Q4 | 743 Million USD | -0.13% |
| 2022 Q2 | 761 Million USD | 4.1% |
| 2022 Q1 | 731 Million USD | -2.14% |
| 2022 FY | - USD | -1.82% |
| 2022 Q3 | 744 Million USD | -2.23% |
| 2021 Q3 | 714 Million USD | -7.75% |
| 2021 FY | - USD | 74.99% |
| 2021 Q1 | 634 Million USD | -31.31% |
| 2021 Q2 | 774 Million USD | 22.08% |
| 2021 Q4 | 747 Million USD | 4.62% |
| 2020 Q3 | 564 Million USD | 133.06% |
| 2020 Q4 | 923 Million USD | 63.65% |
| 2020 FY | - USD | -36.7% |
| 2020 Q1 | 523 Million USD | -34.13% |
| 2020 Q2 | 242 Million USD | -53.73% |
| 2019 Q3 | 674 Million USD | -1.03% |
| 2019 Q2 | 681 Million USD | 2.1% |
| 2019 FY | - USD | 3.46% |
| 2019 Q1 | 667 Million USD | -7.49% |
| 2019 Q4 | 794 Million USD | 17.8% |
| 2018 Q3 | 621 Million USD | -3.27% |
| 2018 Q1 | 636 Million USD | -5.36% |
| 2018 Q2 | 642 Million USD | 0.94% |
| 2018 Q4 | 721 Million USD | 16.1% |
| 2018 FY | - USD | 11.06% |
| 2017 Q1 | 540 Million USD | -6.9% |
| 2017 FY | - USD | 15.5% |
| 2017 Q4 | 672 Million USD | 12.0% |
| 2017 Q3 | 600 Million USD | -4.76% |
| 2017 Q2 | 630 Million USD | 16.67% |
| 2016 FY | - USD | 10.92% |
| 2016 Q1 | 519 Million USD | 5.27% |
| 2016 Q2 | 537 Million USD | 3.47% |
| 2016 Q3 | 567 Million USD | 5.59% |
| 2016 Q4 | 580 Million USD | 2.29% |
| 2015 Q4 | 493 Million USD | 6.25% |
| 2015 Q3 | 464 Million USD | 5.22% |
| 2015 FY | - USD | 10.13% |
| 2015 Q2 | 441 Million USD | -2.22% |
| 2015 Q1 | 451 Million USD | 0.89% |
| 2014 FY | - USD | 5.4% |
| 2014 Q2 | 415 Million USD | -0.72% |
| 2014 Q4 | 447 Million USD | 9.83% |
| 2014 Q3 | 407 Million USD | -1.93% |
| 2014 Q1 | 418 Million USD | 4.5% |
| 2013 Q1 | 373 Million USD | -12.24% |
| 2013 Q3 | 401 Million USD | -4.3% |
| 2013 Q4 | 400 Million USD | -0.25% |
| 2013 FY | - USD | -2.63% |
| 2013 Q2 | 419 Million USD | 12.33% |
| 2012 Q4 | 425 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Phreesia, Inc. | -102.94 Million USD | 3609.641% |
| Accuray Incorporated | 9 Million USD | -40004.34% |
| Align Technology, Inc. | 799.03 Million USD | -352.168% |
| Elevance Health Inc. | 10.49 Billion USD | 65.558% |
| AxoGen, Inc. | -13.32 Million USD | 27208.343% |
| CVS Health Corporation | 18.17 Billion USD | 80.124% |
| Cardinal Health, Inc. | 1.97 Billion USD | -82.659% |
| Centene Corporation | -463 Million USD | 880.346% |
| DaVita Inc. | 2.34 Billion USD | -53.978% |
| HCA Healthcare, Inc. | 12.72 Billion USD | 71.598% |
| Hologic, Inc. | 1.29 Billion USD | -178.738% |
| Humana Inc. | -561 Million USD | 744.029% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | -196.715% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | -167.749% |
| Masimo Corporation | 236.7 Million USD | -1426.405% |
| McKesson Corporation | 4.66 Billion USD | 22.584% |
| Patterson Companies, Inc. | 374.75 Million USD | -864.094% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | -108.603% |
| ResMed Inc. | 1.6 Billion USD | -125.766% |
| Henry Schein, Inc. | 943 Million USD | -283.139% |
| Teladoc Health, Inc. | 153.99 Million USD | -2246.15% |
| Universal Health Services, Inc. | 1.74 Billion USD | -107.236% |
| Veeva Systems Inc. | 429.33 Million USD | -741.536% |
| Baxter International Inc. | 2.77 Billion USD | -30.151% |
| Becton, Dickinson and Company | 4.27 Billion USD | 15.485% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | -50.913% |
| Danaher Corporation | 7.49 Billion USD | 51.82% |
| Stryker Corporation | 5.16 Billion USD | 29.981% |
| Medtronic plc | 9.05 Billion USD | 60.104% |